×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Sodium Glucose Cotransporter 2 Inhibitor Market

ID: MRFR/HC/37501-HCR
100 Pages
Rahul Gotadki
October 2025

ナトリウムグルコース共輸送体2(SGLT2)阻害剤市場調査レポート:薬剤タイプ別(ダパグリフロジン、カナグリフロジン、エンパグリフロジン、エルツグリフロジン)、投与経路別(経口、静脈内)、用途別(2型糖尿病、心不全、慢性腎臓病)、流通チャネル別(病院薬局、小売薬局、オンライン)薬局)および地域別(北米、ヨーロッパ、南米、アジア太平洋、中東、アフリカ) - 2034 年までの予測

共有
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Sodium Glucose Cotransporter 2 Inhibitor Market Infographic
Purchase Options

Sodium Glucose Cotransporter 2 Inhibitor Market 概要

Sodium Glucose Cotransporter 2 Inhibitor Market市場の主要企業には以下が含まれます

レポートの範囲

コメントを残す

FAQs

What is the current valuation of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Market?

The market valuation was 10.02 USD Billion in 2024.

What is the projected market size for the SGLT2 Inhibitor Market by 2035?

The market is expected to reach 33.89 USD Billion by 2035.

What is the expected CAGR for the SGLT2 Inhibitor Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 11.71%.

Which drug types are leading in the SGLT2 Inhibitor Market?

Dapagliflozin, Canagliflozin, Empagliflozin, and Ertugliflozin are the leading drug types.

What are the projected revenues for Dapagliflozin by 2035?

Dapagliflozin is projected to generate revenues of 10.0 USD Billion by 2035.

How does the route of administration impact the SGLT2 Inhibitor Market?

The oral route is expected to generate 20.0 USD Billion, while intravenous administration is projected at 13.89 USD Billion by 2035.

What applications are driving growth in the SGLT2 Inhibitor Market?

Type 2 Diabetes, Heart Failure, and Chronic Kidney Disease are key applications driving market growth.

What is the revenue projection for Type 2 Diabetes applications by 2035?

The revenue for Type 2 Diabetes applications is projected to reach 13.0 USD Billion by 2035.

Which distribution channels are most significant in the SGLT2 Inhibitor Market?

Hospital pharmacies, retail pharmacies, and online pharmacies are significant distribution channels.

What are the projected revenues for retail pharmacies in the SGLT2 Inhibitor Market by 2035?

Retail pharmacies are expected to generate revenues of 13.0 USD Billion by 2035.

無料サンプルをダウンロード

このレポートの無料サンプルを受け取るには、以下のフォームにご記入ください

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions